Attovia Therapeutics prices $289 million IPO ahead of Nasdaq debut

Attovia Therapeutics priced its initial public offering at $17.00 per share, selling 17,000,000 shares of common stock in an offering expected to close on August 6, 2026. The offering is set to raise $289,000,000 before underwriting discounts and commissions of $20,230,000, leaving proceeds before expenses of $268,770,000.¹ The underwriters also received a 30-day option to buy up to 2,550,000 additional shares to cover over-allotments.¹ The stock has been approved for listing on the Nasdaq Global Market under the symbol "ATTO."¹

The company describes itself as focused on biologics for immune conditions where current treatments fall short, built on its ATTOBODY platform. Its lead program, ATTO-1310, targets interleukin-31 and finished dosing patients and healthy volunteers in a Phase 1 study during the first quarter of 2026¹. A second candidate, ATTO-2306, targets both IL-13 and IL-31 and is in IND-enabling studies, with a Phase 1 trial expected to start in the first half of 2027¹. A third program, ATTO-1091, is designed to block TL1A, IL-23 and integrin a4β7 at once and remains in IND-enabling studies¹.

On the balance sheet, Attovia estimated it held approximately $115.1 million in cash, cash equivalents and marketable securities as of June 30, 2026¹, though the company cautioned this figure is preliminary, unaudited and subject to change pending completion of its quarter-end closing process¹. Net losses totaled $39.8 million in 2024 and $60.6 million in 2025¹, with an accumulated deficit of $129.7 million as of March 31, 2026¹. The company said it plans to use offering proceeds along with existing cash to fund operations into 2029¹.